Patent US4877791A successfully refreshed from Google Patents.
US4877791A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Method of treatment for interestitial cystitis
Assignee: Teva Branded Pharmaceutical Products R&D Inc
•
Filing: 1988-11-01
•
Granted: 1989-10-31
•
Expires: 2008-11-01
Abstract
Abstract A method of treating patients suffering from interstitial cystitis comprises daily administration to such patients of from about 1 to about 50 mg of the narcotic antagonists nalmefene or naltrexone. The nalmefene or naltrexone may be administered in equally divided doses from one to four times daily, preferably by the oral route. Parenteral administration may be utilized where suitable.
Inventors
- 👤 Fred P. Sherman
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-08 02:12
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/33; A61K31/395; A61K31/435; A61K31/47; A61K31/485; A61P; A61P13/00; A61P13/02; A61P15/00; A61P29/00
Claims Analysis
Total Claims: 9
Claim 1
Independent Claim
29 words
A method of treating a patient suffering from interstitial cystitis comprising the daily administration to the patient of from about 1 to about 50 mg of nalmefene or naltrexone.
Claim 2
Independent Claim
29 words
A method of treating a patient suffering from interstitial cystitis comprising the daily administration to the patient of from about 1 to about 50 mg of nalmefene or naltrexone.
Claim 3
Dependent Claim
17 words
A method according to claim 1 wherein the nalmefene or naltrexone is administered to the patient orally.
Claim 4
Dependent Claim
38 words
A method according to claim 2 wherein the nalmefene or naltrexone is administered to the patient in an oral dosage form comprising a tablet, capsule, caplet or liquid containing from about 0.5 to about 25.0 mg of nalmefene.
Claim 5
Dependent Claim
17 words
A method according to claim 1 wherein the nalmefene or naltrexone is administered to the patient parenterally.
Claim 6
Dependent Claim
24 words
A method according to claim 4 wherein the nalmefene or naltrexone is administered to the patient by the subcutaneous, intramuscular, intravenous or intravesical routes.
Claim 7
Dependent Claim
22 words
A method according to claim 1 wherein the nalmefene or naltrexone is administered to the patient from one to four times daily.
Claim 8
Dependent Claim
22 words
A method according to claim 6 wherein the nalmefene or naltrexone is administered to the patient from one to two times daily.
Claim 9
Dependent Claim
40 words
A method according to claim 7 wherein 1 mg of nalmefene or naltrexone is administered to a patient twice daily for an initial period, after which the dosage amount is gradually increased to a maximum of 25 mg twice daily.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1992-10-30 | 1993-05-01 | 1993-10-31 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1996-10-30 | 1997-05-01 | 1997-10-31 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2000-10-30 | 2001-05-01 | 2001-10-31 | $7700.00 | Window Closed / Lapsed |